Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

News in Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

Hill-Rom buys Aspen Surgical for $400 million. Life Technologies obtains lung cancer prognostic test. More news briefs.

You may also be interested in...



Reimbursement In Brief

CMS issues proposed decision memo on ocular photodynamic therapy and opens national coverage analyses for cardiac pacemakers and bariatric surgery. GAO denies Palmetto’s Medicare award protest. More reimbursement news.

Regulatory News In Brief

News on FDA workforce troubles, feedback on CDRH’s eCopy policy and more.

News In Brief

Teleflex buys Hotspur, unloads OEM ortho unit. Life Technologies snaps up Navigenics. Accuray acquires Morphormics. More news briefs.

Table

View full table

Related Content

Medtech Insight
Medtech Insight
Medtech Insight

Topics

Related Companies

Tags:
Medical Device
Latest Headlines

Why Investing In ESG Measures Is Good For Medtech’s Health And Sustainability

IVD DNA Test For Cancer Receives New Regulatory Classification

Minute Insight: Medtronic May Sell Respiratory And Monitoring Units To Private Equity

Stakeholders Give FDA An Earful; Poor Communication, Recall Inefficiency, Patients At Risk

See All
UsernamePublicRestriction

Register

MT031431

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By